

OM PHARMA NEWS

OM Pharma and Medinfar enter into exclusive agreement to promote Broncho-Vaxom® in Portugal

*OM Pharma enters into a promotion agreement granting Medinfar the exclusive right
to promote the immunological therapy Broncho-Vaxom®
for the prevention of respiratory tract infections in Portugal*

Geneva, Switzerland, 5 September 2022 - The promotion agreement grants Medinfar, a Portuguese pharmaceutical group, the exclusive right to promote OM Pharma's Broncho-Vaxom® (Bacterial Lysates - OM-85) in Portugal.

Broncho-Vaxom® is a therapeutic agent that prevents recurrent respiratory tract infections in adult and paediatric patients by boosting the host immunity.

This agreement marks yet another synergistic collaboration with a leading local player, demonstrating OM Pharma's ability to establish strategic partnerships. The longstanding commercial experience of Medinfar will consolidate the position of Broncho-Vaxom® in Portugal and strengthen OM Pharma's impact in the field of respiratory and immunological diseases to support more patients who are suffering from recurrent respiratory tract infections.

For more information, please contact:

Magalie Blandin
Head of Corporate Communications
media@ompharma.com
Tel.: +41 22 783 11 11

###

About OM Pharma

OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections and is also active in the treatment of vascular diseases.



It operates in about 100 countries thanks to a strong network of international partners and invests its profits in R&D to develop microbial derived immunotherapeutic products to treat acute and chronic immunological disorders resulting from inflammation and infections.

On 30 September 2020, Etienne Jornod, former Executive Chairman of Vifor Pharma and Galenica, acquired the company together with entrepreneurs and strategic partner, Abdi Ibrahim, with the ambition to continue its global expansion and to invest CHF 250 million in R&D and manufacturing capacity expansion.

The company strives to improve the quality of life of patients around the world by providing access to better treatment of immunological imbalances.

For more information, visit the website: www.ompharma.com

About Broncho-Vaxom®

Broncho-Vaxom® is an extract of different bacterial species used for the prevention of recurrent respiratory tract infections for both adults and children. It stimulates the immune system and the body's natural defense against a wide spectrum of viral and bacterial respiratory pathogens.

Broncho-Vaxom® is now approved in 64 countries around the world (for treating adults and children).¹

About Medinfar

Medinfar Group is a Portuguese pharmaceutical company, founded in 1970. Medinfar is present throughout the different life cycle of pharmaceutical products, from R&D and manufacturing to marketing and sales.

Medinfar has a strong presence in the Rx medicines sector, with a vast and innovative portfolio focusing on cardiovascular / metabolic and respiratory diseases.

Medinfar is a leading company in Portugal in the Consumer Health and Dermatology sectors. Internationally, the company has an affiliate in Morocco (Medinfar Morocco) and commercial agreements in more the 50 countries worldwide.

For more information, visit the website: <https://www.medinfar.com>

¹ Derived from sales data by OM Pharma